Privium Fund Management B.V. Intra Cellular Therapies, Inc. Transaction History
Privium Fund Management B.V.
- $354 Million
- Q2 2024
A detailed history of Privium Fund Management B.V. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 117,983 shares of ITCI stock, worth $8.64 Million. This represents 2.28% of its overall portfolio holdings.
Number of Shares
117,983
Previous 108,883
8.36%
Holding current value
$8.64 Million
Previous $7.53 Million
7.25%
% of portfolio
2.28%
Previous 2.23%
Shares
5 transactions
Others Institutions Holding ITCI
# of Institutions
400Shares Held
87.2MCall Options Held
309KPut Options Held
302K-
Vanguard Group Inc Valley Forge, PA9.61MShares$703 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$463 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.72MShares$272 Million1.37% of portfolio
-
Jpmorgan Chase & CO New York, NY3.44MShares$251 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$220 Million2.8% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $6.91B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...